Subscribe To

Price Alert Latest News Economic Calendar News

VCEL / Vericel Corp (VCEL) CEO Dominick Colangelo on Q1 2022 Results - Earnings Call Transcript

Vericel Corp (NASDAQ:VCEL ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Eric Burns - Executive Director, Financial Planning and Analysis & IR Dominick Colangelo - CEO, President & Director Joseph Mara - CFO & Treasurer Conference Call Participants Ryan Zimmerman - BTIG Christopher Cooley - Stephens Inc. Jeffrey Cohen - Ladenburg Thalmann & Co. Danielle Antalffy - SVB Leerink Samuel Brodovsky - Truist Securities Arthur He - H.C. Wainwright & Co. Operator Ladies and gentlemen, thank you for standing by. Read More

Demo Live Account See Partner Details

Content Topics

Vericel

Corp

VCEL

Dominick

Colangelo

2022

Results

Earnings

vcel

Transcript

Stock

Posted: May 4 2022, 17:31

Author Name: Seeking Alpha

VCEL News

By Seeking Alpha
June 27, 2023

Vericel: Multiyear Growth Catalysts, Proprietary Solutions Will Drive Market Cap Expansion

Vericel Corporation demonstrates consistent growth in its core product lines, including MACI for cartilage repair and Epicel for severe burn treatment

By Zacks Investment Research
May 10, 2023

Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates

Vericel Corporation (VCEL) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to

By GlobeNewsWire
April 26, 2023

Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and sev

By Seeking Alpha
April 2, 2023

Vericel Corporation: A Promising Future In Advanced Cell Therapies

The FDA's recent approval of NexoBrid for the treatment of burns is expected to drive revenue growth in 2023. Vericel's MACI autologous cell therapy p

By Seeking Alpha
February 23, 2023

Vericel Corporation (VCEL) Q4 2022 Earnings Call Transcript

Vericel Corporation (NASDAQ:VCEL ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Eric Burns – Head-Financial Pl

By Zacks Investment Research
January 12, 2023

Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains?

Vericel Corporation (VCEL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estima

By GlobeNewsWire
January 4, 2023

Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and seve

By Seeking Alpha
January 1, 2023

Vericel: Aggressive Growth In 2023

Various ongoing fundamental improvements signal significant upsides. The recent NexoBrid approval foretells leaping sales growth in the coming quarter

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.